{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:25:05Z","timestamp":1786922705497,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>GEN1<\/jats:italic>\n                      gene is involved in DNA damage repair, as are several prostate cancer susceptibility genes, and is now included in several NGS clinical testing panels. The aim of our study was to investigate the role of\n                      <jats:italic>GEN1<\/jats:italic>\n                      mutations in the etiology of prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      First, we sequenced\n                      <jats:italic>GEN1<\/jats:italic>\n                      in 390 Polish men with familial prostate cancer and 300 population controls using exome sequencing to identify protein-truncating variants and to analyze their possible association with prostate cancer risk. In addition, we performed a large association study of a recurrent frameshift variant of\n                      <jats:italic>GEN1<\/jats:italic>\n                      (c.1929_1932delAAAG) among 5,857 men with unselected prostate cancer and 3,956 controls. We compared the clinical characteristics of prostate tumors in carriers of c.1929_1932delAAAG and in non-carriers. We conducted loss of heterozygosity (LOH) analysis at the\n                      <jats:italic>GEN1<\/jats:italic>\n                      locus in prostate cancers from two men with the c.1929_1932delAAAG variant. To analyze survival, patients were followed from diagnosis to death for an average of 101 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We detected two frameshift variants (c.2515_2519delAAGTT (p. Lys839Glufs*2), c.1539delT (p. Asp514Ilefs*13)) by sequencing the\n                      <jats:italic>GEN1<\/jats:italic>\n                      gene of 390 Polish patients with familial prostate cancer and 300 cancer-free controls. Neither variant was associated with increased prostate cancer risk: c.2515_2519delAAGTT was detected in 20.5% of 390 cases and in 17.1% of 300 controls (p\u2009=\u20090.28), c.1539delT was detected in one case (0.3%) and none of the controls (p\u2009=\u20091.00). The\n                      <jats:italic>GEN1<\/jats:italic>\n                      variant, c.1929_1932delAAAG (p. Lys645Cysfs*29), was observed in 13 of 5,857 (0.22%) unselected cases and 8 of 3,956 (0.20%) controls (OR = 1.10, p = 0.84). Clinical characteristics of prostate tumors in 13 carriers of c.1929_1932delAAAG and 5,844 non-carriers were similar. All-cause survival was similar for variant carriers and non-carriers (age-adjusted HR = 0.68, p = 0.76). The wild-type\n                      <jats:italic>GEN1<\/jats:italic>\n                      allele was not lost in two prostate tumors in men with the c.1929_1932delAAAG variant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our analysis suggests that\n                      <jats:italic>GEN1<\/jats:italic>\n                      is not a prostate cancer susceptibility gene. The study has clinical implications for genetic counseling of men who tested positive for germline variants of\n                      <jats:italic>GEN1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00343-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:36:09Z","timestamp":1781084169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association analysis of germline variants in GEN1 with a susceptibility to prostate cancer in Polish men"],"prefix":"10.1186","volume":"24","author":[{"given":"Katarzyna","family":"Gliniewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Stempa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Woko\u0142orczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Klu\u017aniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Kilja\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Huzarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Uci\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"D\u0119bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Grabarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jakubowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Szwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Lener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Cybulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"343_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"343_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315(1):68\u201376. https:\/\/doi.org\/10.1001\/jama.2015.17703.","journal-title":"JAMA"},{"issue":"8","key":"343_CR3","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","volume":"89","author":"BS Carter","year":"1992","unstructured":"Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992;89(8):3367\u201371. https:\/\/doi.org\/10.1073\/pnas.89.8.3367.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"343_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.2990170409","volume":"17","author":"GD Steinberg","year":"1990","unstructured":"Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337\u201347. https:\/\/doi.org\/10.1002\/pros.2990170409.","journal-title":"Prostate"},{"issue":"15","key":"343_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","unstructured":"Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310\u20136. https:\/\/doi.org\/10.1093\/jnci\/91.15.1310.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"343_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1110000.","journal-title":"N Engl J Med"},{"issue":"20","key":"343_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"JP Struewing","year":"1997","unstructured":"Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401\u20138. https:\/\/doi.org\/10.1056\/NEJM199705153362001.","journal-title":"N Engl J Med"},{"issue":"2","key":"343_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1086\/346094","volume":"72","author":"X Dong","year":"2003","unstructured":"Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72(2):270\u201380. https:\/\/doi.org\/10.1086\/346094.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"343_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1158\/0008-5472.can-03-2502","volume":"64","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, Debniak T, Gliniewicz B, Mierzejewski M, Masoj\u0107 B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004;64(4):1215\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2502.","journal-title":"Cancer Res"},{"issue":"2","key":"343_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.bjc.6604847","volume":"100","author":"Z Kote-Jarai","year":"2009","unstructured":"Kote-Jarai Z, Jugurnauth S, Mulholland S, Leongamornlert DA, Guy M, Edwards S, et al. A recurrent truncating germline mutation in the BRIP1\/FANCJ gene and susceptibility to prostate cancer. Br J Cancer. 2009;100(2):426\u201330. https:\/\/doi.org\/10.1038\/sj.bjc.6604847.","journal-title":"Br J Cancer"},{"issue":"14","key":"343_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","volume":"31","author":"VM Raymond","year":"2013","unstructured":"Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013;31(14):1713\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.44.1238.","journal-title":"J Clin Oncol"},{"issue":"23","key":"343_CR12","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673\u201381. https:\/\/doi.org\/10.1002\/cncr.30248.","journal-title":"Cancer"},{"issue":"9","key":"343_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/carcin\/21.8.1623","volume":"21","author":"C Voelkel-Johnson","year":"2000","unstructured":"Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R, Maggouta F, Kurtz DT, et al. Genomic instability-based transgenic models of prostate cancer. Carcinogenesis. 2000;21(9):1623\u20137. PMID: 10910968.","journal-title":"Carcinogenesis"},{"issue":"4","key":"343_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","volume":"125","author":"D Woko\u0142orczyk","year":"2021","unstructured":"Woko\u0142orczyk D, Klu\u017aniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569\u201375. https:\/\/doi.org\/10.1038\/s41416-021-01410-0.","journal-title":"Br J Cancer"},{"issue":"3","key":"343_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","volume":"27","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247\u201354. https:\/\/doi.org\/10.1038\/85798.","journal-title":"Nat Genet"},{"issue":"6","key":"343_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/35073057","volume":"2","author":"DM Lilley","year":"2001","unstructured":"Lilley DM, White MF. The junction-resolving enzymes. Nat Rev Mol Cell Biol. 2001;2(6):433\u201343. https:\/\/doi.org\/10.1038\/35073057.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"343_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0092-8674(95)90191-4","volume":"83","author":"A Schwacha","year":"1995","unstructured":"Schwacha A, Kleckner N. Identification of double Holliday junctions as intermediates in meiotic recombination. Cell. 1995;83(5):783\u201391. https:\/\/doi.org\/10.1016\/0092-8674(95)90191-4.","journal-title":"Cell"},{"issue":"7290","key":"343_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature08868","volume":"464","author":"M Bzymek","year":"2010","unstructured":"Bzymek M, Thayer NH, Oh SD, Kleckner N, Hunter N. Double Holliday junctions are intermediates of DNA break repair. Nature. 2010;464(7290):937\u201341. https:\/\/doi.org\/10.1038\/nature08868.","journal-title":"Nature"},{"issue":"9","key":"343_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1128\/MCB.01130-10","volume":"31","author":"TM Ashton","year":"2011","unstructured":"Ashton TM, Mankouri HW, Heidenblut A, McHugh PJ, Hickson ID. Pathways for Holliday junction processing during homologous recombination in Saccharomyces cerevisiae. Mol Cell Biol. 2011;31(9):1921\u201333. https:\/\/doi.org\/10.1128\/MCB.01130-10.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"343_CR20","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/nar\/gky1280","volume":"47","author":"MA Sobhy","year":"2019","unstructured":"Sobhy MA, Brali\u0107 A, Raducanu VS, Takahashi M, Tehseen M, Rashid F, et al. Resolution of the Holliday junction recombination intermediate by human GEN1 at the single-molecule level. Nucleic Acids Res. 2019;47(4):1935\u201349. https:\/\/doi.org\/10.1093\/nar\/gky1280.","journal-title":"Nucleic Acids Res"},{"key":"343_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/bs.mie.2017.11.020","volume":"600","author":"YW Chan","year":"2018","unstructured":"Chan YW, West SC. GEN1 endonuclease: purification and nuclease assays. Methods Enzymol. 2018;600:527\u201342. https:\/\/doi.org\/10.1016\/bs.mie.2017.11.020.","journal-title":"Methods Enzymol"},{"issue":"13","key":"343_CR22","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.3390\/ijms26135991","volume":"26","author":"K Gliniewicz","year":"2025","unstructured":"Gliniewicz K, Woko\u0142orczyk D, Klu\u017aniak W, Stempa K, Huzarski T, Rudnicka H, et al. Analysis of GEN1 as a breast cancer susceptibility gene in polish women. Int J Mol Sci. 2025;26(13):5991. https:\/\/doi.org\/10.3390\/ijms26135991.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"343_CR23","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/ijc.33272","volume":"147","author":"D Woko\u0142orczyk","year":"2020","unstructured":"Woko\u0142orczyk D, Klu\u017aniak W, Huzarski T, Gronwald J, Szymiczek A, Rusak B, et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int J Cancer. 2020;147(10):2793\u2013800. https:\/\/doi.org\/10.1002\/ijc.33272.","journal-title":"Int J Cancer"},{"issue":"2","key":"343_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/bjc.2012.486","volume":"108","author":"C Cybulski","year":"2013","unstructured":"Cybulski C, Woko\u0142orczyk D, Klu\u017aniak W, Jakubowska A, G\u00f3rski B, Gronwald J, et al. An inherited NBN mutation is associated with poor prognosis prostate cancer. Br J Cancer. 2013;108(2):461\u20138. https:\/\/doi.org\/10.1038\/bjc.2012.486.","journal-title":"Br J Cancer"},{"issue":"7\u20138","key":"343_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF02401826","volume":"31","author":"DK Lahiri","year":"1993","unstructured":"Lahiri DK, Schnabel B. DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet. 1993;31(7\u20138):321\u20138. https:\/\/doi.org\/10.1007\/BF02401826.","journal-title":"Biochem Genet"},{"issue":"4","key":"343_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/cancers17040613","volume":"17","author":"S Feszak","year":"2025","unstructured":"Feszak S, Feszak IJ, Klu\u017aniak W, Woko\u0142orczyk D, Stempa K, Gliniewicz K, et al. BRCA1 and BRCA2 mutations in Polish women with ductal carcinoma in situ. Cancers (Basel). 2025;17(4):613. https:\/\/doi.org\/10.3390\/cancers17040613.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"343_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1158\/0008-5472.can-03-2502","volume":"64","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, D\u0119bniak T, Gliniewicz B, Mierzejewski M, Masoj\u0107 B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004;64(4):1215\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2502.","journal-title":"Cancer Res"},{"issue":"10","key":"343_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/dna.2015.3022","volume":"35","author":"X Wang","year":"2016","unstructured":"Wang X, Wang H, Guo B, Zhang Y, Gong Y, Zhang C, et al. Gen1 and Eme1 play redundant roles in DNA repair and meiotic recombination in mice. DNA Cell Biol. 2016;35(10):585\u201390. https:\/\/doi.org\/10.1089\/dna.2015.3022.","journal-title":"DNA Cell Biol"},{"issue":"6","key":"343_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.devcel.2018.05.020","volume":"45","author":"M Arter","year":"2018","unstructured":"Arter M, Hurtado-Nieves V, Oke A, Zhuge T, Wettstein R, Fung JC, et al. Regulated crossing-over requires inactivation of Yen1\/GEN1 resolvase during meiotic prophase I. Dev Cell. 2018;45(6):785\u2013e8006. https:\/\/doi.org\/10.1016\/j.devcel.2018.05.020.","journal-title":"Dev Cell"},{"issue":"1","key":"343_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10549-010-0949-1","volume":"124","author":"C Turnbull","year":"2010","unstructured":"Turnbull C, Hines S, Renwick A, Seal S, Parker A, Elliott A, et al. Mutation and association analysis of GEN1 in breast cancer susceptibility. Breast Cancer Res Treat. 2010;124(1):283\u20138. https:\/\/doi.org\/10.1007\/s10549-010-0949-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"343_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C, et al. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1913948.","journal-title":"N Engl J Med"},{"issue":"3","key":"343_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2019.01.050","volume":"76","author":"DA Leongamornlert","year":"2019","unstructured":"Leongamornlert DA, Saunders EJ, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, et al. Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel. Eur Urol. 2019;76(3):329\u201337. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.050.","journal-title":"Eur Urol"},{"issue":"11","key":"343_CR33","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","volume":"9","author":"BF Darst","year":"2023","unstructured":"Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, et al. Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer. JAMA Oncol. 2023;9(11):1514\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3482.","journal-title":"JAMA Oncol"},{"issue":"14","key":"343_CR34","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1101\/gad.585310","volume":"24","author":"U Rass","year":"2010","unstructured":"Rass U, Compton SA, Matos J, Singleton MR, Ip SC, Blanco MG, et al. Mechanism of Holliday junction resolution by the human GEN1 protein. Genes Dev. 2010;24(14):1559\u201369. https:\/\/doi.org\/10.1101\/gad.585310.","journal-title":"Genes Dev"},{"issue":"7220","key":"343_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nature07470","volume":"456","author":"SC Ip","year":"2008","unstructured":"Ip SC, Rass U, Blanco MG, Bai X, Flynn HR, Skehel JM, et al. Identification of Holliday junction resolvases from humans and yeast. Nature. 2008;456(7220):357\u201361. https:\/\/doi.org\/10.1038\/nature07470.","journal-title":"Nature"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00343-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:42:44Z","timestamp":1786920164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00343-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00343-0","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Pomeranian Medical University in Szczecin approved the study (IRB No KB-0012\/97\/17). Patient clinical data have been obtained in a manner conforming to IRB ethical guidelines.","order":1,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"17"}}